Skip to main content
. 2020 Jun 1;25(10):e1481–e1491. doi: 10.1634/theoncologist.2019-0982

Figure 4.

Figure 4

Prognostic value of the IHC‐based classification of TNBC. (A): Kaplan‐Meier curves for RFS according to the IHC‐based classification in the original cohort (n = 210). (B): Time‐dependent AUC of multivariate Cox models to predict relapse in the original cohort (n = 210). (C): Kaplan‐Meier curves for RFS according to the IHC‐based classification in the validation cohort 1 (n = 183). (D): Time‐dependent AUC of the multivariate Cox models established in the original cohort to predict relapse in the validation cohort 1 (n = 183). (E): Kaplan‐Meier curves for RFS according to the IHC‐based classification in the validation cohort 2 (n = 214). (F): Time‐dependent AUC of the multivariate Cox models established in the original cohort to predict relapse in the validation cohort 2 (n = 214). “T” and “N” refer to the pathological T category and pathological N category of tumors, respectively.

Abbreviations: AUC, area under the curve; BLIS, basal‐like immune‐suppressed; IHC, immunohistochemistry; IM, immunomodulatory; LAR, luminal androgen receptor; MES, mesenchymal; RFS, relapse‐free survival; UC, unclassifiable.